Meridian Bioscience Company Profile (NASDAQ:VIVO)

Analyst Ratings

Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $21.00 (3.70% upside)

Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Canaccord GenuityReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Robert W. BairdReiterated RatingHold$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Hilliard LyonsUpgradeNeutral -> Buy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016William BlairReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Craig HallumBoost Price TargetBuy$21.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/2/2015Raymond James Financial Inc.DowngradeMarket Perform -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Meridian Bioscience (NASDAQ:VIVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/25/2016        
7/25/2016N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.22$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.21$0.23ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/25/2012$0.19$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2011$0.19$0.18ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/21/2011$0.21$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2011$0.20$0.20ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/20/2011$0.19$0.15ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.24$0.25$0.25
Q2 20161$0.21$0.21$0.21
Q3 20161$0.20$0.20$0.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)
Annual Dividend:$0.80
Dividend Yield:3.95%
Payout Ratio:95.24% (Based on Trailing 12 Months of Earnings)
91.95% (Based on Current Year Consensus EPS Estimate)
86.02% (Based on Next Year Consensus EPS Estimate)

Dividend History for Meridian Bioscience (NASDAQ:VIVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
4/28/2016quarterly$0.204.19%5/5/20165/9/20165/19/2016Tweet This Announcement  Share This Announcement on StockTwits
1/27/2016quarterly$0.204.29%2/4/20162/8/20162/18/2016Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015quarterly$0.203.89%11/12/201511/16/201511/27/2015Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015quarterly$0.204.28%7/30/20158/3/20158/13/2015Tweet This Announcement  Share This Announcement on StockTwits
4/23/2015quarterly$0.204.18%4/30/20155/4/20155/14/2015Tweet This Announcement  Share This Announcement on StockTwits
1/22/2015quarterly$0.204.51%1/29/20152/2/20152/13/2015Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014quarterly$0.204.75%11/13/201411/17/201411/28/2014Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014quarterly$0.203.99%7/31/20148/4/20148/14/2014Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014quarterly$0.204.05%5/1/20145/5/20145/15/2014Tweet This Announcement  Share This Announcement on StockTwits
1/22/2014quarterly$0.203.13%1/30/20142/3/20142/14/2014Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013quarterly$0.193.04%11/14/201311/18/201311/29/2013Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013quarterly$0.193.13%8/1/20138/5/20138/15/2013Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013quarterly$0.193.88%5/1/20135/4/20135/14/2013Tweet This Announcement  Share This Announcement on StockTwits
12/4/2012quarterly$0.1912/14/201212/24/2012Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Meridian Bioscience (NASDAQ:VIVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
DateHeadline
07/07/16 09:50 AMMeridian Bioscience Inc. (VIVO) is Trading Lower on Unusual Volume for July 05
07/01/16 04:26 PMMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : July 1, 2016 -
07/01/16 09:47 AMMeridian Bioscience Inc. (VIVO) is Trading Higher on Unusual Volume for June 29
06/30/16 07:21 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : June 30, 2016 -
06/23/16 07:55 PMMeridian Bioscience Inc. (VIVO) is Trading Lower on Unusual Volume for June 21
06/15/16 07:49 AMMeridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae - [at noodls] - CINCINNATI, June 15, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. ...
06/06/16 12:35 PMMERIDIAN BIOSCIENCE INC Files SEC form 8-K/A, Financial Statements and Exhibits -
06/02/16 06:15 AMBioline Launches New MyTaq™ Plant-PCR Kit - [at noodls] - CINCINNATI, June 02, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq™ Plant-PCR ...
05/04/16 11:17 AMMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2016 By the Numbers -
05/04/16 11:17 AMMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2016 By the Numbers -
04/29/16 10:07 AMMERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition -
04/29/16 10:07 AMMERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition -
04/28/16 07:31 AMMeridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2016 Guidance - CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., (NASDAQ:VIVO) today: reported fiscal 2016 second quarter and first six months net revenues of $51.3 million and $98.4 million, respectively, decreases of 1% from the same periods of ...
04/27/16 06:21 AMMeridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae - [at noodls] - CINCINNATI, April 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. ...
04/27/16 06:21 AMMeridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae - [at noodls] - CINCINNATI, April 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. ...
04/26/16 11:46 AMMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : April 26, 2016 -
04/26/16 11:46 AMMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : April 26, 2016 -
04/26/16 11:14 AMETF’s with exposure to Meridian Bioscience, Inc. : April 26, 2016 -
04/26/16 11:14 AMETF’s with exposure to Meridian Bioscience, Inc. : April 26, 2016 -
04/25/16 07:12 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : April 25, 2016 -
04/25/16 07:12 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : April 25, 2016 -
03/29/16 07:05 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : March 29, 2016 -
03/29/16 07:05 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : March 29, 2016 -
03/24/16 04:26 PMBRIEF-Meridian Bioscience says bought Magellan Diagnostics for $66 mln - * Meridian expects Magellan to be accretive to earnings per share during second half of calendar 2017
02/09/16 01:51 PMMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : February 9, 2016 -
02/09/16 07:57 AMMERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report -
02/09/16 07:02 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : February 9, 2016 -
02/03/16 01:14 PMMeridian Bioscience Breaks Below 200-Day Moving Average - Notable for VIVO - In trading on Tuesday, shares of Meridian Bioscience Inc. (VIVO) crossed below their 200 day moving average of $18.65, changing hands as low as $18.48 per share. Meridian Bioscience Inc. shares are currently trading off about 2.5% on the day. The chart ...
02/02/16 10:30 AMMeridian Bioscience Q1 Earnings in Line, Sales Miss Mark -
02/01/16 09:30 AMMERIDIAN BIOSCIENCE INC Files SEC form 8-K/A, Results of Operations and Financial Condition -
01/29/16 11:55 AMMeridian Bioscience, Inc. Earnings Analysis: Q1, 2016 By the Numbers -
01/27/16 12:30 PMMeridian Bioscience Inc. Earnings Climb 13% In Q1 - (RTTNews.com) - Meridian Bioscience Inc. ( VIVO) announced a profit for its first quarter that climbed from last year. The company said its bottom line advanced to $8.89 million, or $0.21 per share. This was higher than $7.90 million, or $0.19 per share ...
01/27/16 06:49 AMMeridian Bioscience meets 1Q profit forecasts -
01/27/16 06:44 AMMeridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance - [at noodls] - GENERAL HIGHLIGHTS , (GLOBE NEWSWIRE) -- , (NASDAQ:VIVO) today: reported first quarter net revenues of , a decrease of 2% from the same period of the prior fiscal year; reported first quarter operating ...
01/26/16 01:08 PMMeridian Bioscience, Inc.: New Malaria Test, illumigene® Malaria, Sets a New Gold Standard for Diagnosis - Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for illumigene® Malaria, a novel, highly accurate test developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC ...
01/26/16 09:19 AMMeridian Bioscience and Lean Continuous Improvements, LLC Collaborate to Apply Lean Principles to Recent Launch of illumigene® Malaria - [at noodls] - , (GLOBE NEWSWIRE) -- announced today that the recent product transfer and launch of its innovative molecular test illumigene Malaria was accomplished on an accelerated schedule via a collaboration with ...
01/26/16 09:02 AM10:02 am Meridian Bioscience announces the recent product transfer and launch of its molecular test illumigene Malaria was accomplished on an accelerated schedule via a collaboration with Lean Continuous Improvements -
01/26/16 06:30 AMNew Malaria Test, illumigene® Malaria, Sets a New Gold Standard for Diagnosis - [GlobeNewswire] - CINCINNATI, Jan. 26, 2016-- Meridian Bioscience, Inc. today announced that it has received the CE Mark for illumi gene ® Malaria, a novel, highly accurate test developed by Meridian with the technical ...
01/23/16 12:03 PMMeridian Bioscience, Inc. (VIVO) - Meridian Bioscience, Inc., a life science company, develops, manufactures, and distributes diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company operates through ...
01/05/16 07:52 AMMeridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 -
12/30/15 12:10 PMMeridian Bioscience at 52-Week High on Product Launches -
12/24/15 04:02 PMDiagnostics Firm, Trash Hauler Make Noteworthy Highs -
12/16/15 01:01 PMMeridian Bioscience, Inc. Earnings Analysis: Q4, 2015 By the Numbers -
12/09/15 09:48 AMBioline Launches New JetSeq™ DNA Library Preparation Kit - [at noodls] - CINCINNATI--(BUSINESS WIRE)--Dec. 9, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the JetSeq™ DNA ...
12/08/15 12:18 PMMERIDIAN BIOSCIENCE INC Financials -
11/30/15 08:07 AMMERIDIAN BIOSCIENCE INC Files SEC form 10-K, Annual Report -
11/25/15 07:40 AMHedge Funds Aren’t Crazy About Meridian Bioscience, Inc. (VIVO) Anymore -
11/18/15 12:00 PMMeridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims - [Business Wire] - Meridian Bioscience, Inc. today announced it has received clearance from the U.S. Food and Drug Administration for new claims for its illumigene® Pertussis molecular amplification test. The upgraded test reduces the effect of inhibitors in biologic samples and significantly expands Meridian’s customer base by including specimens collected by ESwab™ .
11/13/15 01:45 PMMeridian Bioscience (VIVO) Buys Stake in Oasis, Shares Fall -
11/13/15 11:30 AMCincinnati firm ‘takes a nibble’ of possible acquisition -

Social

About Meridian Bioscience

Meridian Bioscience logoMeridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: VIVO
  • CUSIP: 58958410
Key Metrics:
  • Previous Close: $20.25
  • 50 Day Moving Average: $19.58
  • 200 Day Moving Average: $19.70
  • P/E Ratio: 24.11
  • P/E Growth: 1.44
  • Market Cap: $852.00M
  • Beta: 1.18
  • Current Year EPS Consensus Estimate: $0.87 EPS
  • Next Year EPS Consensus Estimate: $0.93 EPS
Additional Links:
Meridian Bioscience (NASDAQ:VIVO) Chart for Monday, July, 25, 2016